The double-blind randomised, placebo-controlled, clinical prospective study on pain reduction in patients with cervical spine syndrome, available on our study page, stands as one of the most conclusive pieces of evidence supporting the efficacy of Bioresonance according to Paul Schmidt. It demonstrates that our approach works with waves of success in the truest sense of the word. The results of the study are published in this book.
The study treated patients with chronic pain, i.e. pain that had been present for more than two years. The results of the study suggest a new approach to treatment, particularly for chronic pain. Naturopaths, alternative practitioners, and patients can have confidence in the safe and effective use of Bioresonance according to Paul Schmidt with approved medical products, such as the Rayocomp PS 1000 polar 4.0 med. and the Rayocomp PS 10 med. Treatment with the Rayocomp PS 1000 polar 4.0 med. showed a significant improvement, as you can see in the following extracts from the final report.
Findings published in the final report include:
- ‘No significant improvement was achieved for neck pain, headaches, back pain, shoulder pain and tension when treated with the placebo, whereas all parameters showed significant improvements (p<0.001) when treated with the Rayocomp bioresonance device […].’ (p.34)
- ‘With regard to physical performance, no significant improvement was achieved with the placebo treatment, while all parameters showed significant improvements (p<0.001) when treated with the Rayocomp bioresonance device […].’ (p.37)
- ‘Overall, there was a clear difference when asked if a patient would recommend the treatment to others. All patients in the Rayocomp group answered positively, while only around a quarter of the patients in the placebo group did the same.’ (p.42)
- ‘Furthermore, it was confirmed that the Rayocomp PS 1000 polar 4.0 bioresonance device is safe.’ (p.21)
